Shenzhen Weiguang Biological Products Co Ltd (002880) - Total Liabilities
Based on the latest financial reports, Shenzhen Weiguang Biological Products Co Ltd (002880) has total liabilities worth CN¥1.04 Billion CNY (≈ $151.80 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Shenzhen Weiguang Biological Products Co to assess how effectively this company generates cash.
Shenzhen Weiguang Biological Products Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Shenzhen Weiguang Biological Products Co asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Shenzhen Weiguang Biological Products Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Weiguang Biological Products Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Theravance Biopharma Inc
NASDAQ:TBPH
|
USA | $188.85 Million |
|
M Grass Ecology and Environment Group Co Ltd
SHE:300355
|
China | CN¥10.06 Billion |
|
Yatharth Hospital & Trauma Care Services Limited
NSE:YATHARTH
|
India | Rs-16.37 Billion |
|
Shinkong Synthetic Fiber Corp
TW:1409
|
Taiwan | NT$168.08 Billion |
|
Tsakos Energy Navigation Ltd
NYSE:TEN
|
USA | $2.06 Billion |
|
Ratos AB (publ)
ST:RATO-B
|
Sweden | Skr12.45 Billion |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
|
China | CN¥287.66 Million |
|
Omada Health, Inc. Common Stock
NASDAQ:OMDA
|
USA | $70.12 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Shenzhen Weiguang Biological Products Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Shenzhen Weiguang Biological Products Co worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Weiguang Biological Products Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Weiguang Biological Products Co Ltd (2012–2024)
The table below shows the annual total liabilities of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.05 Billion ≈ $154.12 Million |
+26.72% |
| 2023-12-31 | CN¥831.14 Million ≈ $121.62 Million |
+17.36% |
| 2022-12-31 | CN¥708.20 Million ≈ $103.63 Million |
+229.04% |
| 2021-12-31 | CN¥215.23 Million ≈ $31.49 Million |
+1.35% |
| 2020-12-31 | CN¥212.36 Million ≈ $31.08 Million |
+55.42% |
| 2019-12-31 | CN¥136.64 Million ≈ $19.99 Million |
-11.00% |
| 2018-12-31 | CN¥153.53 Million ≈ $22.47 Million |
-10.49% |
| 2017-12-31 | CN¥171.52 Million ≈ $25.10 Million |
-57.48% |
| 2016-12-31 | CN¥403.44 Million ≈ $59.04 Million |
-12.72% |
| 2015-12-31 | CN¥462.25 Million ≈ $67.64 Million |
+0.33% |
| 2014-12-31 | CN¥460.73 Million ≈ $67.42 Million |
-5.76% |
| 2013-12-31 | CN¥488.91 Million ≈ $71.54 Million |
-7.86% |
| 2012-12-31 | CN¥530.63 Million ≈ $77.65 Million |
-- |
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous inj… Read more